Good Morning Market Enthusiast,

In 2014, a quiet biotech made a move that barely registered on the radar. No buzz. No hype. Just steady clinical progress.

Then Phase 3 data dropped.

And just like that — Xiidra was acquired for up to $5.3 billion. (7)

People who noticed early weren’t surprised. 

They’d been watching the build-up. 

The rest? They were left wondering how they missed it.

Fast-forward to 2025, and something eerily similar is unfolding again.

Different name. Bigger need. More leverage.

This time, it’s OKYO Pharma Limited (Nasdaq:OKYO).

(5)

And this time, the playbook isn’t just repeating — it’s evolving.

And recently received some fresh analyst coverage that just confirmed what early-watchers have been sensing — OKYO could have over 230% upside from here.

🗞️ Fresh Report. Major Upside Potential (1)(3)(6)

Yesterday, OKYO closed at $2.07. 

But recently Wall Street stamped it with a $7.00 price target — a potential +230% move from current levels.

That’s not a pipe dream. 

That’s from H.C. Wainwright — one of the few firms that actually understands this space. 

They just reiterated their B-u-y rating and laid out the math:
 

• The Phase 2a trial for neuropathic corneal pain (NCP) is enrolling now
• Data is due in Q4 2025 and if it hits, OKYO owns the only FDA-cleared path to treat this debilitating pain
• Their dry eye data already showed strong pain relief — the same kind of symptom that defines NCP
• The valuation model alone puts OKYO’s worth at $300 million, which translates to $7 per share assuming moderate success
   

That’s not speculation. 

It’s DCF-modeled, risk-adjusted valuation — even applying just a 5% probability of NCP approval and 35% for DED. Conservative. Methodical. 

Yet still pointing to a multi-bagger setup.

Bottom line? The upside is mathematically real and underpriced. 

That gap doesn’t last forever.

🟢 The company has already started moving.
🟢 The clock is ticking toward data.
🟢 And the upside is still wide open.

Don’t wait for the headline. Get in front of it.

(14)

👁️ A condition no one treats… yet (8)(11)(13)

Most have never heard of neuropathic corneal pain (NCP).

That’s because there’s no approved medication to treat it. None.

But for those who suffer from it? It’s constant, severe, often debilitating — the kind of eye pain that destroys sleep, focus, and quality of life.

OKYO Pharma Limited (Nasdaq:OKYO) is the first company ever to receive FDA clearance to begin a controlled trial for NCP. 

Not repurposing old dru.gs. Not exploring off-label options. This is the first clinically validated attempt to directly address it.

Their candidate, Urcosimod, is a non-steroidal, non-opioid topical therapy designed to address both pain and inflammation on the ocular surface.

And in May 2025, the FDA granted it Fast Track designation — signaling regulatory confidence and unlocking a streamlined development path.

That trial is now live.

Data? Expected by Q4 2025.

And OKYO is defining the category. From scratch. 🛠️

(5)
 

🔬 Not a moonshot. A methodical build. (10)(11)(12)(13)

What gives this edge credibility is that Urcosimod has already delivered.

In 2023, OKYO completed a 240-patient Phase 2 trial for dry eye disease (DED) — a massive global market with tens of millions of patients and multiple blockbuster medications.

Urcosimod didn’t just squeak by. It hit targets that others routinely miss:
 

• Significant improvement in eye surface damage by Day 29
• Pain relief by Day 15
• Improved vision symptoms by the end of the trial
• Safety on par with placebo — no steroids, no opioids, no serious events
  
   

Dry eye trials are notoriously tricky. Many fail to show both sign relief and symptom improvement.

OKYO’s trial showed both, in its very first human study.

That’s why insiders doubled down.

That’s why the FDA gave them a green light to go faster.

That’s why attention is now shifting to what comes next.

🔍 Undervalued and underexposed … for now (9)

Here’s what makes this moment unusual:

Despite clinical success, regulatory traction, and a pipeline built on firsts, OKYO is still trading at a market cap of ~$70 million.

Compare that to:
 

• Dry eye peers like Aldeyra (~$150M–$160M), also in mid-to-late stage
• Recent takeouts like Aerie Pharmaceuticals (~$770M)
• Or Xiidra — the poster child — at over $5B
   

The mismatch is clear. 

The reason? Timing.

OKYO Pharma Limited (Nasdaq:OKYO) hasn’t hit its next data drop yet. 

And once it does, that number likely won’t stay low.

This kind of gap — where the clinical progress is ahead of the market reaction — rarely lasts.

📆 The next inflection point is already scheduled

OKYO’s NCP trial is ongoing now.

The design is tight. The endpoints are clear. 

The science has support.

Top-line data is expected in Q4 2025.

That will be the defining moment — not just for OKYO, but for the field itself.

If the results are strong?
 

• OKYO becomes the only company with a clinically validated treatment for NCP
• Conversations about licensing, partnerships, or strategic combinations start becoming real
• The market reassesses everything — and fast
   

Remember: Urcosimod already showed signs of pain reduction in dry eye patients.

This isn’t a wild leap. It’s a logical extension. 

And the mechanism is built for it.

🧠 Most won’t realize what they missed… until it’s obvious

Every cycle has a few companies like this.

The ones that made big strides quietly.

That stayed small while building real traction.

That were ahead of the narrative — and had data to back it up.

By the time headlines hit, the price changes. The game changes.

Right now, OKYO is:

✅ First to trial in a wide-open disease space
✅ Backed by strong dry eye data
✅ Aligned internally — from insiders to creditors
✅ On-track to deliver a potential first-ever solution in NCP
✅ Operating with a valuation that doesn’t reflect what’s been built

The match is lit.

And the fuse is burning.

🔍 You’ve seen this pattern before 🔷

Small team. Big science. Low market cap. Real data. Upcoming catalyst.

It’s never about waiting for confirmation — by the time everyone agrees, the move is over.

Right now, you’re early.

But not for long.

The data clock is ticking. The market is watching.

And in the months ahead, everything will get louder.

🟢 Check out  OKYO Pharma Limited (Nasdaq:OKYO) Now!

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://finance.yahoo.com/quote/OKYO/ 
2. https://finance.yahoo.com/quote/OKYO/key-statistics/
3. https://finance.yahoo.com/quote/OKYO/history/ 
4. https://okyopharma.com/
5. https://okyopharma.com/wp-content/uploads/2024/07/OKYO-Slide-Deck-for-July.pdf
6. https://okyopharma.com/wp-content/uploads/2025/02/OKYO-FEB-25-Phase-2a-Trial-in-NCP-to-Complete-Enrollment-in-2Q25-Reiter.pdf
7.  https://bit.ly/45jdShe
8. https://www.ophthalmologymanagement.com/news/2025/okyo-pharma-to-complete-enrollment-of-neuropathic-corneal-pain-trial-by-end-of-q2/
9. https://www.biopharmadive.com/news/aerie-pharmaceuticals-alcon-deal-glaucoma/630267/
10. https://okyopharma.com/wp-content/uploads/2023/09/OKYO_Enrollment-PR_FINAL_GJ.pdf
11. https://okyopharma.com/technology/
12. https://glance.eyesoneyecare.com/stories/2025-05-05/fda-grants-fast-track-designation-to-okyo-pharma-s-ncp-therapeutic/
13. https://glance.eyesoneyecare.com/stories/2025-04-02/okyo-s-urcosimod-demonstrates-long-term-stability-for-ncp/
14. https://bit.ly/3FI1jSd

Paid Promotion. Momentum Media LLC has been hired for a period beginning on 06/10/2025 and ending on 06/11/2025 (the “Campaign”) to publicly disseminate information about OKYO Pharma Limited (OKYO:US). Momentum Media LLC has been compensated $10,000.00 and are owed an additional $0 for the Campaign. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is financial advice. Momentum Media LLC is not an analyst, st.o.ck broker, financial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.